Lymphatic Diseases  >>  Torisel (temsirolimus)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

2 Trials

Remove FilterRemove FilterRemove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Torisel (temsirolimus) / Pfizer
NCT01170052 / 2009-014844-13: Bendamustine and Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Non-Hodgkin's Lymphoma (NHL)

Withdrawn
1/2
20
Europe
Temsirolimus, Torisel®, Bendamustine
Charite University, Berlin, Germany, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma K.K.
Mantle Cell Lymphoma
04/12
04/14
BERT, NCT01078142 / 2009-013351-30: Temsirolimus, Bendamustine and Rituximab for Relapsed Follicular Lymphoma or Mantle Cell Lymphoma

Checkmark ICML 2013
Jun 2013 - Jun 2013: ICML 2013
Checkmark Interim P1/2 data in FL, MCL
Nov 2011 - Nov 2011: Interim P1/2 data in FL, MCL
Completed
1/2
39
Europe
Temsirolimus, Rituximab, Bendamustin, Mabthera, Rituxan, Torisel, Bendamustin, Ribomustin, Trenda
Georg Hess, MD, Wyeth is now a wholly owned subsidiary of Pfizer, Mundipharma Pte Ltd.
Follicular Lymphoma, Mantle Cell Lymphoma
09/17
09/17

Download Options